Nobiletin inhibits neonatal rat cardiomyocytes hypertrophy induced by high glucose
10.12092/j.issn.1009-2501.2021.07.005
- Author:
Xiaoping LIU
1
;
Zizhang OUYANG
1
;
Sheng JIANG
1
;
Ying ZHANG
1
;
Xiangmao LAI
2
Author Information
1. Department of Pharmacy, the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
2. Department of Urology, the Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital
- Publication Type:Journal Article
- Keywords:
Cardiomyocyte hypertrophy;
High glucose;
Nobiletin;
Nrf2/HO-1 signaling pathway
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2021;26(7):753-759
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To investigate the effect of nobiletin (Nob) on cardiomyocyte hypertrophy induced by high glucose and its mechanism. METHODS: Neonatal rat cardiomyocytes (NRCMS) were stimulated with high glucose (HG) to establish cardiomyocyte hypertrophy and nobiletin was given. Cell viability was measured by MTT assay. C-myc and Nppa mRNA levels were detected by qRT-PCR. Cellular surface area was detected by immunofluorescence, and Nrf2 and HO-1 protein expressions were detected by Western blot. RESULTS: After stimulation with 33.3 mmol/L HG for 48 h, the survival rate of NRCMS was significantly decreased, C-myc, Nppa mRNA levels and cellular surface area were significantly increased, Nrf2 and HO-1 protein expression were significantly decreased (P<0.05). After Nob treatment, compared with HG group, cellular surface area, Nrf2 and HO-1 protein expression were significantly increased, C-myc and Nppa mRNA levels were significantly decreased. The above indexes were reversed by using Nrf2 inhibitor. CONCLUSION: Nob inhibits cardiomyocyte hypertrophy induced by high glucose, and its mechanism may be related to the activation of Nrf2/HO-1 signaling pathway.
